Vertex Pharmaceuticals Future Growth
Future criteria checks 3/6
Vertex Pharmaceuticals is forecast to grow earnings and revenue by 11.2% and 8.6% per annum respectively. EPS is expected to grow by 10.2% per annum. Return on equity is forecast to be 22.8% in 3 years.
Key information
11.2%
Earnings growth rate
10.2%
EPS growth rate
Biotechs earnings growth | 20.6% |
Revenue growth rate | 8.6% |
Future return on equity | 22.8% |
Analyst coverage | Good |
Last updated | 25 Mar 2024 |
Recent future growth updates
Recent updates
Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth
Mar 21Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?
Mar 15Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run
Feb 28We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings
Feb 22Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452
Feb 07Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
Jan 22With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Jan 15Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Dec 25An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued
Nov 13With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Oct 02Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jul 31We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease
Jul 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 22% Undervalued
Apr 30With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case
Apr 03An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 24% Undervalued
Jan 23If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity
Jan 02Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 47%?
Oct 24Vertex to advance two AAT correctors to potentially treat rare, genetic disease
Oct 11Do Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings Warrant Your Attention?
Oct 02Vertex in licensing agreement with MaxCyte to use platform for gene editing candidate
Sep 28Vertex Pharmaceuticals: Clinical Data Supports A Favorable Long-Term Growth Outlook
Sep 19Vertex wins FDA label expansion for cystic fibrosis drug to add younger children
Sep 02Vertex: CF Monopoly, Looking To Expand
Aug 05Vertex to run late-stage studies for pain therapy in 4Q 2022
Jul 22Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 12,908 | 5,101 | 5,329 | 5,460 | 24 |
12/31/2025 | 11,739 | 4,498 | 4,613 | 4,867 | 30 |
12/31/2024 | 10,731 | 3,895 | 4,285 | 4,840 | 30 |
12/31/2023 | 9,869 | 3,620 | 3,279 | 3,537 | N/A |
9/30/2023 | 9,654 | 3,470 | 4,205 | 4,381 | N/A |
6/30/2023 | 9,505 | 3,365 | 3,879 | 4,068 | N/A |
3/31/2023 | 9,208 | 3,260 | 3,890 | 4,074 | N/A |
12/31/2022 | 8,931 | 3,322 | 3,925 | 4,130 | N/A |
9/30/2022 | 8,701 | 3,273 | 3,814 | 4,047 | N/A |
6/30/2022 | 8,350 | 3,195 | 3,787 | 4,018 | N/A |
3/31/2022 | 7,948 | 2,451 | 2,451 | 2,679 | N/A |
12/31/2021 | 7,574 | 2,342 | 2,409 | 2,644 | N/A |
9/30/2021 | 7,130 | 2,176 | 1,919 | 2,140 | N/A |
6/30/2021 | 6,684 | 1,992 | 1,777 | 2,121 | N/A |
3/31/2021 | 6,415 | 2,762 | 3,048 | 3,359 | N/A |
12/31/2020 | 6,206 | 2,712 | 2,994 | 3,254 | N/A |
9/30/2020 | 5,991 | 2,691 | 2,979 | 3,208 | N/A |
6/30/2020 | 5,403 | 2,081 | 2,557 | 2,635 | N/A |
3/31/2020 | 4,819 | 1,511 | 1,983 | 2,060 | N/A |
12/31/2019 | 4,163 | 1,177 | 1,494 | 1,569 | N/A |
9/30/2019 | 3,620 | 2,144 | 1,363 | 1,438 | N/A |
6/30/2019 | 3,454 | 2,215 | 1,413 | 1,484 | N/A |
3/31/2019 | 3,265 | 2,155 | 1,258 | 1,342 | N/A |
12/31/2018 | 3,048 | 2,096 | 1,175 | 1,270 | N/A |
9/30/2018 | 2,829 | 647 | 1,060 | 1,183 | N/A |
6/30/2018 | 2,623 | 415 | 682 | 972 | N/A |
3/31/2018 | 2,415 | 226 | 554 | 832 | N/A |
12/31/2017 | 2,489 | 263 | 586 | 845 | N/A |
9/30/2017 | 2,296 | 196 | N/A | 762 | N/A |
6/30/2017 | 2,131 | 259 | N/A | 658 | N/A |
3/31/2017 | 2,019 | 177 | N/A | 517 | N/A |
12/31/2016 | 1,702 | -112 | N/A | 236 | N/A |
9/30/2016 | 1,661 | -219 | N/A | 121 | N/A |
6/30/2016 | 1,557 | -275 | N/A | -7 | N/A |
3/31/2016 | 1,292 | -399 | N/A | -158 | N/A |
12/31/2015 | 1,032 | -556 | N/A | -365 | N/A |
9/30/2015 | 759 | -659 | N/A | -576 | N/A |
6/30/2015 | 628 | -734 | N/A | -602 | N/A |
3/31/2015 | 600 | -704 | N/A | -620 | N/A |
12/31/2014 | 580 | -738 | N/A | -573 | N/A |
9/30/2014 | 787 | -582 | N/A | -362 | N/A |
6/30/2014 | 830 | -530 | N/A | -289 | N/A |
3/31/2014 | 1,002 | -428 | N/A | -162 | N/A |
12/31/2013 | 1,212 | -504 | N/A | -61 | N/A |
9/30/2013 | 1,195 | -559 | N/A | -40 | N/A |
6/30/2013 | 1,309 | -499 | N/A | 80 | N/A |
3/31/2013 | 1,417 | -506 | N/A | 199 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VRTX's forecast earnings growth (11.2% per year) is above the savings rate (2.3%).
Earnings vs Market: VRTX's earnings (11.2% per year) are forecast to grow slower than the US market (13.4% per year).
High Growth Earnings: VRTX's earnings are forecast to grow, but not significantly.
Revenue vs Market: VRTX's revenue (8.6% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: VRTX's revenue (8.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VRTX's Return on Equity is forecast to be high in 3 years time (22.8%)